KRAS and lung carcinoma: The discovery of druggable targets such as epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), MET, ROS-1receptor tyrosine kinase and Kirsten rat sarcoma viral oncogene homolog (KRAS) open avenues for treating lung cancer [4,5].